NY Politician Participates In Clinical Trial For COVID-19 Vaccine

NEW YORK, NY — State Sen. Brad Hoylman began participating this week in a clinical trial within the NYU Grossman School of Medicine for a COVID-19 vaccine.

The Manhattan lawmaker, whose district stretches from the West Village to Central Park, is specifically participating in a phase 3 clinical trial for a COVID-19 vaccine under the supervision of the NYU Langone Health's Vaccine Center.

"The development of a COVID-19 vaccine is our generation's moonshot," Hoylman said in a news release. "As a staunch advocate for science-based health policy to combat vaccine-preventable illnesses, I'm proud to have done my part joining a clinical trial for a COVID-19 vaccine at the Vaccine Center at NYU Langone Health."

"If this or other vaccine candidates are successful, we'll be able to stem the human suffering caused by COVID-19, protect our front line workers and vulnerable New Yorkers from infection, and hopefully soon resume our daily lives," Hoylman added in the news release.

Hoylman is also urging other New Yorkers to find out if they qualify to join a COVID-19 vaccine trial.

If one of the current vaccine candidates receives regulatory approval, it is predicted that the manufacturer will produce up to 100 million doses by the end of 2020, according to NYU Langone Health.

You can find out more about joining a vaccine trial at coronaviruspreventionnetwork.org.